Early diagnosis, early treatment, and compliance are particularly important for early patients. Some scholars believe that the first three months of the onset of the disease is the “treatment time window”, and that treatment in this period plays an important role in prognosis. However, this period is actually very difficult to grasp, especially if the patient is not too concerned about the symptoms, and may not be able to grasp this period if they do not see a doctor in time, 類風濕性關節炎or the examination methods of the hospital, or the clinical ability of the doctor.
However, no matter what our working hours are, it is not too late for standard treatment, standardization and treatment for rheumatoid patients diagnosed in China. For many patients in the middle or late stages, it may not be easy to achieve remission, and “low disease activity” can be combined with drug therapy as the goal.
Once the “treatment standard” is achieved, can the drug be reduced and stopped with confidence? In reality, doctors generally allow the patient to maintain relief for half a year. In more high-level treatments, rheumatoid patients have a high chance of reaching the treatment standard, especially in the early stages.
In the process of drug reduction and drug withdrawal, patients should respect the doctor’s professional ability, communicate with the doctor, and must not reduce or stop the drug without authorization. The patient reduces the dose by himself, and there is no problem with stopping the drug within a certain period of time, but there may be hidden dangers for short-term recurrence.
In the process of realizing standardized treatment, the level of hospitals and doctors may be the limiting factor. After all, there are regional differences in China’s medical level and medical resources.類風濕性關節炎 In these aspects, the growing Internet medical model and chronic disease management may help us to a certain extent.
Another important issue is an economic restriction. Standard treatment, if biological agents are included, it may be an easily available treatment target. If biological agents are not used, it will be more difficult to achieve treatment standards, and even some patients may not achieve treatment standards, and the drugs cannot be stopped or even reduced. This is also the true and realistic side of rheumatoid arthritis, which is difficult to treat.
The last question comes from the patient. Different patients have different diseases, that is, rheumatoid itself is very heterogeneous. At the same time, the course of the disease is different, and the difficulty of treatment is also different. For patients in the middle and late stages and patients with a long course, it is relatively more difficult to achieve standard treatment than those in the early stage.
When the patient understands the status of the treatment technology for rheumatoid arthritis, it may be possible to gain a better understanding of the students’ own treatment, understand our own doctors, compare and study the requirements for drug reduction and withdrawal, and be more scientific, pragmatic and rational. Improve treatment and rehabilitation.related articles:
related articles:
Rheumatoid arthritis concept and its clinical significance
mergencyr博客 